561307-54-8

Basic information

• Product Name: cis-(4-Hydroxy-cyclohexyl)-Methyl-carbaMic acid tert-butyl ester
• Synonyms: cis-(4-Hydroxy-cyclohexyl)-Methyl-carbaMic acid tert-butyl ester;tert-Butyl (cis-4-hydroxycyclohexyl)(methyl)carbamate
• CAS NO: 561307-54-8
• Molecular Formula: C₁₂H₂₃NO₃
• Molecular Weight: 229.31592
• Mol File: 561307-54-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 319.2±31.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3(Predicted)
• PKA: 15.09±0.40(Predicted)
• CAS DataBase Reference: cis-(4-Hydroxy-cyclohexyl)-Methyl-carbaMic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: cis-(4-Hydroxy-cyclohexyl)-Methyl-carbaMic acid tert-butyl ester(561307-54-8)
• EPA Substance Registry System: cis-(4-Hydroxy-cyclohexyl)-Methyl-carbaMic acid tert-butyl ester(561307-54-8)

Safety Data

• Hazardous Substances Data: 561307-54-8(Hazardous Substances Data)

Upstream product

• 1332632-63-9 benzoic acid 4-cis-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl ester 
• 400899-99-2 tert-butyl ((1r,4r)-4-hydroxycyclohexyl)(methyl)carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 22348-38-5 cis-4-Methylamino-cyclohexanol-⁽¹⁾ 

Downstream Products

• 1007306-59-3 cis-1-methanesulphonyloxy-4-[N-(tert-butyloxycarbonyl)-N-methyl-amino]-cyclohexane 

Relevant articles and documents

4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2, 3 - D] PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS

The present invention relates to novel thienopyrimidine compounds of general formula (I), pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

6-SUBSTITUTED ISOQUINOLINE DERIVATIVES

The present invention relates to 6-substituted isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 0 or 1; o is 0 or 1; R1 is H, when Y is NH2; or R1 is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R4 is H or (C1-6)alkyl, optionally substituted with halogen, (C3-7)cycloalkyl, (C6-10)aryl or a saturated 5- or 6-membered heterocyclic ring comprising 1-3 heteroatoms independently selected from O, S and N, the (C6-10)aryl and heterocyclic ring being optionally substituted with (C1-4)alkyl, (C1-4)alkyloxy or halogen; R5 is H or (C1-4)alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that the compounds of Formula I wherein X is O, Y is OH , n is 0 and m+o=2 are excluded, to pharmaceutical compositions comprising the same, as well as to the use of said 6-substituted isoquinoline derivatives for the preparation of a medicament for the treatment of ROCK-I related disorders such as glaucoma, hypertension and atherosclerosis.